Study of Circulating Microparticles in Giant Cell Arteritis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02333708

Acronym

MicroGiant

Enrollment

Registered

2015-01-07

Start date

2015-09-30

Completion date

2023-11-30

Last updated

2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Phase, Giant Cell Arteritis

Brief summary

To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

Interventions

OTHERBlood sample

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

For GCA group: Inclusion Criteria: * Men and women ≥ 18 years of age Patient affiliated to social security regimen * Informed and having signed the consent form to take part in the study. * Diagnosis of GCA, meeting at least 3 of the following 5 American College of Rheumatology (ACR) criteria for the diagnosis of GCA, including inflammatory syndrome and having * Either temporal artery biopsy showing characteristic GCA abnormality * Or inflammatory arteritis on imaging examination

Exclusion criteria

* Persons under protection of the court or guardianship * Inability to understand or to follow study procedures * Dementia * cancer diagnosed within the previous 5 years (except for non-melanoma skin cancer or in situ carcinoma of the cervix)non-contributory or inconclusive temporal artery biopsy * Any conditions that might interfere with MPs level: diabetes, recent endo-arterial gesture, current treatment with corticosteroids. * Participation in another ongoing clinical trial Current anticoagulant therapy * Active infectious disease

Design outcomes

Primary

Measure	Time frame	Description
Level of microparticles in the blood of patients with histologically proven giant cell arteritis.	Baseline	Level of microparticles (MPs) in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

Countries

France

Contacts

Primary ContactBoris BIENVENU, MD, PhD,

bienvenu-b@chu-caen.fr+33231064579

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026